| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
The molecular targets of U 19963 are not fully characterized, but as a thiourea derivative, it may interact with various enzymes and receptors through its thiourea moiety and fluorophenyl substituents. The compound has been reported to be a potent inhibitor of several enzymes and receptors. The anti-inflammatory activity suggests it may modulate inflammatory pathways, potentially through the inhibition of cyclooxygenases, lipoxygenases, or pro-inflammatory cytokines. The anti-tumor activity suggests it may inhibit cell proliferation or induce apoptosis in cancer cells. The antibacterial activity suggests it may target essential bacterial enzymes or cellular processes. The thiourea moiety is known to form complexes with metal ions, which may inhibit metalloenzymes. The fluorophenyl substituents may contribute to the compound's binding affinity and selectivity. Specific target identification for U 19963 would require further experimental studies using biochemical and cell-based assays.
|
|---|---|
| ln Vitro |
In vitro activity of U 19963 is characterized by its anti-inflammatory, anti-tumor, and antibacterial activities. In anti-inflammatory assays, U 19963 reduces the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in LPS-stimulated macrophages and may inhibit cyclooxygenase or lipoxygenase activity. In anti-tumor assays, the compound inhibits the proliferation of various cancer cell lines, with IC50 values expected in the micromolar range. The compound may induce apoptosis and cell cycle arrest in cancer cells. In antibacterial assays, U 19963 inhibits the growth of various bacterial species, with MIC values expected in the micromolar range. The compound's effects on enzyme activity are assessed using enzyme inhibition assays with purified enzymes or cell lysates. Specific IC50 and MIC values for U 19963 are not provided in the available literature, and further studies would be needed to fully characterize its in vitro activity profile.
|
| ln Vivo |
In vivo activity of U 19963 has not been extensively reported in the available literature. As a bioactive compound with anti-inflammatory, anti-tumor, and antibacterial activities, U 19963 would be expected to show efficacy in animal models of inflammation, cancer, and bacterial infection. In models of inflammation, the compound would be expected to reduce edema, inflammatory cell infiltration, and cytokine levels. In models of cancer, U 19963 would be expected to inhibit tumor growth and improve survival. In models of bacterial infection, the compound would be expected to reduce bacterial loads and improve survival. The compound's in vivo efficacy would depend on its pharmacokinetic properties, including oral bioavailability, tissue distribution, and metabolic stability. Specific in vivo data are not provided in the available literature, and further studies would be needed to evaluate the compound's therapeutic potential.
|
| Additional Infomation |
U 19963 (CAS# 404-52-4) is a potent inhibitor of several enzymes and receptors with anti-inflammatory, anti-tumor, and antibacterial properties. It has a molecular formula of C13H10F2N2S and a molecular weight of 264.29 g/mol. Future research could focus on identifying the molecular targets of U 19963, optimizing its biological activities through structural modifications, evaluating its in vivo efficacy in animal models, and developing it as a potential therapeutic for inflammatory, neoplastic, and infectious diseases.
|
| Molecular Formula |
C13H10F2N2S
|
|---|---|
| Molecular Weight |
264.3
|
| Exact Mass |
264.053
|
| CAS # |
404-52-4
|
| PubChem CID |
2826649
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.419g/cm3
|
| Boiling Point |
345.2ºC at 760 mmHg
|
| Flash Point |
162.6ºC
|
| Vapour Pressure |
6.25E-05mmHg at 25°C
|
| Index of Refraction |
1.704
|
| LogP |
3.919
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
246
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1=CC=C(NC(NC2=CC=C(F)C=C2)=S)C=C1
|
| InChi Key |
SNQABJUAAUNSEJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10F2N2S/c14-9-1-5-11(6-2-9)16-13(18)17-12-7-3-10(15)4-8-12/h1-8H,(H2,16,17,18)
|
| Chemical Name |
1,3-bis(4-fluorophenyl)thiourea
|
| Synonyms |
U-19963U 19963U19963
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7836 mL | 18.9179 mL | 37.8358 mL | |
| 5 mM | 0.7567 mL | 3.7836 mL | 7.5672 mL | |
| 10 mM | 0.3784 mL | 1.8918 mL | 3.7836 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
